Trial Profile
An observational, real-world study on adherence, persistence and switching of anticoagulants (dabigatran, rivaroxaban, apixaban or warfarin) in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- 28 Nov 2016 New trial record